---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-005536"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2022-04-11T23:59:59+00:00"
generated_at: "2026-06-26T08:12:17.148712+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biodesix raises $11.7M via private placement; amends 2021 term loan with SVB

## Summary
- Sold 6,508,376 shares at $1.79/share to consortium including board members, raising ~$11.7M.
- Third Amendment to 2021 Term Loan: repays $3M in April 2022 and $2M later; waives Q1 2022 minimum revenue requirement.
- Waiver of prepayment fee on $3M repayment; consent for $2M milestone payment under Integrated Diagnostics purchase agreement.
- Reaffirms 2022 revenue guidance of $37.5M-$39.5M.

## SEC filing metadata
- accession: 0000950170-22-005536
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2022-04-11T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017022005536/0000950170-22-005536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017022005536/bdsx-20220407.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-005536
- JSON: https://secwatch.observer/filing/0000950170-22-005536.json
- Plain text: https://secwatch.observer/filing/0000950170-22-005536.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.